SCHEMBL4715980

SCHEMBL4715980

CC(C)CCCC(C)CCCC(C)CCCC(C)CCN1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
CXCR4 P61073 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
BLM P54132 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
SIGMAR1 Q99720 2/20 0.35
CHRM5 P08912 1/20 0.35
CHRM3 P20309 1/20 0.35
GBA1 P04062 2/20 0.35
ALDH1A1 P00352 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22430355 0.85 SIGMAR1 (0.41) CXCR4SMN1; SMN2POLBSIGMAR1CHRM5
SCHEMBL13251374 0.84 CXCR4 (0.50) CXCR4SMN1; SMN2POLBMEN1KMT2A
SCHEMBL104625 0.84 SMN1; SMN2 (0.45) CXCR4SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL27423153 0.82 CXCR4 (0.48) CXCR4SMN1; SMN2POLBSIGMAR1CHRM5
SCHEMBL11932527 0.82 CXCR4 (0.52) CXCR4SMN1; SMN2POLBSIGMAR1CHRM5
SCHEMBL26130440 0.82 LMNA (0.52) LMNABLM
Hydrochloric Acid SCHEMBL25326103 0.82 SMN1; SMN2 (0.43) LMNACXCR4SMN1; SMN2POLBMEN1
SCHEMBL21016068 0.81 CXCR4 (0.55) CXCR4SMN1; SMN2POLBSIGMAR1CHRM5
SCHEMBL22430415 0.81 SMN1; SMN2 (0.39) CXCR4SMN1; SMN2POLBMEN1KMT2A
SCHEMBL14944015 0.81 CXCR4 (0.55) CXCR4SMN1; SMN2POLBSIGMAR1CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 CN disclosed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 LMNA 4180/4885CXCR4 1280/4885SMN1; SMN2 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.